Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| enVVeno Medical CorpHJLI · Entity 8104 | Chief Medical Officer, OUS | November 27, 2018 | November 29, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
enVVeno Medical Corp
Report date November 27, 2018 · Filed November 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Common StockSEC Table I · non-derivative | IndirectBy Rosewall Ventures Ltd. | 437,778 |
Reported balance
After 2018-11-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-11-27 · Grant · Acquired 3,334 · Balance 437,778 F1: The issuer entered into a services agreement with Rosewall Ventures Ltd. ("Rosewall"), dated May 1, 2018 (the "Service Agreement"), whereby Rosewall is providing the services of Ben Broennimann as the Company's Chief Medical Officer - Out of U.S.. The Service Agreement provides for the monthly payment of fifteen thousand dollars ($15,000) (the " Rosewall Monthly Fee"), provided however that the Company may, at its sole option, elect to pay twenty five percent (25%) of the Rosewall Monthly Fee in company common stock, par value $0.0001 per share (the "Common Stock"), with the number of Common Stock determined by dividing three thousand seven hundred fifty dollars ($3,750) by the closing price of Common Stock on the second (2nd) work day of each month. On November 27, 2018, the Company elected to issue Rosewall Common Stock for the months of October and November. F2: The closing price of the Common Stock on the 2nd work day of October was $2.57 and it was $2.00 for the 2nd work day of November. F3: Dr. Benedict Broennimann is the chairman of Rosewall Ventures Ltd. |
Filing footnotes · ownership attribution and instrument terms
F1: The issuer entered into a services agreement with Rosewall Ventures Ltd. ("Rosewall"), dated May 1, 2018 (the "Service Agreement"), whereby Rosewall is providing the services of Ben Broennimann as the Company's Chief Medical Officer - Out of U.S.. The Service Agreement provides for the monthly payment of fifteen thousand dollars ($15,000) (the " Rosewall Monthly Fee"), provided however that the Company may, at its sole option, elect to pay twenty five percent (25%) of the Rosewall Monthly Fee in company common stock, par value $0.0001 per share (the "Common Stock"), with the number of Common Stock determined by dividing three thousand seven hundred fifty dollars ($3,750) by the closing price of Common Stock on the second (2nd) work day of each month. On November 27, 2018, the Company elected to issue Rosewall Common Stock for the months of October and November.
F2: The closing price of the Common Stock on the 2nd work day of October was $2.57 and it was $2.00 for the 2nd work day of November.
F3: Dr. Benedict Broennimann is the chairman of Rosewall Ventures Ltd.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 27, 2018 Filed Nov 29, 2018 22:31 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantRestricted Common Stock | 3,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-016878 · ownership.xml · nonDerivative · entry 1 Broennimann Benedict · CIK 0001730165 · Chief Medical Officer, OUS 10b5-1 filing: Not disclosed Ownership: Indirect · By Rosewall Ventures Ltd. Disclosed balance after: 437,778 F1 · kind: The issuer entered into a services agreement with Rosewall Ventures Ltd. ("Rosewall"), dated May 1, 2018 (the "Service Agreement"), whereby Rosewall is providing the services of Ben Broennimann as the Company's Chief Medical Officer - Out of U.S.. The Service Agreement provides for the monthly payment of fifteen thousand dollars ($15,000) (the " Rosewall Monthly Fee"), provided however that the Company may, at its sole option, elect to pay twenty five percent (25%) of the Rosewall Monthly Fee in company common stock, par value $0.0001 per share (the "Common Stock"), with the number of Common Stock determined by dividing three thousand seven hundred fifty dollars ($3,750) by the closing price of Common Stock on the second (2nd) work day of each month. On November 27, 2018, the Company elected to issue Rosewall Common Stock for the months of October and November. F2 · price: The closing price of the Common Stock on the 2nd work day of October was $2.57 and it was $2.00 for the 2nd work day of November. F3 · ownership.nature: Dr. Benedict Broennimann is the chairman of Rosewall Ventures Ltd. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.